Michael MD - Exagen Chief Officer
| XGN Stock | USD 4.10 0.18 4.59% |
Executive
Michael MD is Chief Officer of Exagen Inc
| Age | 69 |
| Address | 1261 Liberty Way, Vista, CA, United States, 92081 |
| Phone | 760 560 1501 |
| Web | https://www.exagen.com |
Exagen Management Efficiency
The company has Return on Asset of (0.1741) % which means that on every $100 spent on assets, it lost $0.1741. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6997) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Exagen's Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Intangible Assets is likely to grow to about 6.6 M, while Total Assets are likely to drop about 54.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Matthew MD | Castle Biosciences | N/A | |
| Kathleen Hoffman | Sotera Health Co | N/A | |
| Claudia Levi | DarioHealth Corp | N/A | |
| Xiaozhi Hu | Burning Rock Biotech | N/A | |
| Jessica Olbricht | Biodesix | N/A | |
| Jean Muyl | DarioHealth Corp | N/A | |
| Tobin Juvenal | Castle Biosciences | 64 | |
| Joseph Vitale | Sotera Health Co | N/A | |
| Robbie Lunt | Biodesix | N/A | |
| Brian Harrigan | DarioHealth Corp | N/A | |
| Bernhard Spiess | Castle Biosciences | 64 | |
| Josh Fischer | DarioHealth Corp | N/A | |
| Kieran OKane | Biodesix | 47 | |
| Shannon Shoemaker | Psychemedics | 38 | |
| Michael Weisenhoff | Psychemedics | 34 | |
| Danielle Menture | Sotera Health Co | N/A | |
| Daniella Mehalik | Psychemedics | 34 | |
| Kat Parrella | DarioHealth Corp | N/A | |
| Alice Izzo | Castle Biosciences | N/A | |
| Mark DeBlock | Biodesix | N/A | |
| Patrick Kinney | Psychemedics | N/A | |
Management Performance
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.17 |
Exagen Inc Leadership Team
Elected by the shareholders, the Exagen's board of directors comprises two types of representatives: Exagen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exagen. The board's role is to monitor Exagen's management team and ensure that shareholders' interests are well served. Exagen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exagen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Black, Chief Officer | ||
| Debra Zack, Chief Officer | ||
| John Wegener, Senior Marketing | ||
| Ryan Douglas, Investors Officer | ||
| Mark Hazeltine, Chief Officer | ||
| MingChou Lee, Chief Officer | ||
| John Aballi, President, CEO | ||
| Michael MD, Chief Officer | ||
| MD FACR, Chief Board | ||
| MBA MS, Corporate Secretary | ||
| Tina Nova, Executive Directors |
Exagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exagen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 70.66 M | ||||
| Shares Outstanding | 17.64 M | ||||
| Shares Owned By Insiders | 29.74 % | ||||
| Shares Owned By Institutions | 57.21 % | ||||
| Number Of Shares Shorted | 52.21 K | ||||
| Price To Book | 5.37 X |
Pair Trading with Exagen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exagen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will appreciate offsetting losses from the drop in the long position's value.Moving against Exagen Stock
| 0.5 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.43 | KA | Kineta Inc | PairCorr |
| 0.4 | TCHH | Trustcash Holdings | PairCorr |
| 0.34 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Exagen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exagen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exagen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exagen Inc to buy it.
The correlation of Exagen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exagen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exagen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exagen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.